A Phase 1 interventional study of Salmeterol and fluticasone propionate in Healthy, sponsored by Kindeva Drug Delivery. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-15.
Sponsored by Kindeva Drug Delivery · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to test the body's response to several doses of two different inhalation products in healthy volunteers.
Healthy subjects will be enrolled and will receive 2, 6, and 12 inhalations from both the test and reference pMDI products according to a six-period cross-over design. Electrocardiograms (ECGs) and plasma potassium and glucose levels will be measured pre-dose and over 6 hours post-dose.
Kindeva Drug Delivery is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
salmeterol and fluticasone propionate, 2 puffs
Drug: Salmeterol · Drug: fluticasone propionate
salmeterol and fluticasone propionate, 2 puffs
Drug: Salmeterol · Drug: fluticasone propionate
salmeterol and fluticasone propionate, 6 puffs
Drug: Salmeterol · Drug: fluticasone propionate
salmeterol and fluticasone propionate, 6 puffs
Drug: Salmeterol · Drug: fluticasone propionate
salmeterol and fluticasone propionate, 12 puffs
Drug: Salmeterol · Drug: fluticasone propionate
salmeterol and fluticasone propionate, 12 puffs
Drug: Salmeterol · Drug: fluticasone propionate
A, D 2 puffs; B, E 6 puffs; C, F 12 puffs
Also known as: Sirdupla, Seretide Evohaler
A, D 2 puffs; B, E 6 puffs; C, F 12 puffs
Also known as: Sirdupla, Seretide Evohaler
Relative Potency Max Heart Rate
Selection of steepest part of dose response curve for Relative Potency: 6 and 12 inhalation dose pairs. Slope of B and C line compared with slope of E and F to obtain relative potency value. Two inhalation dose not utilized as not on steepest part of curve.
Time frame: Baseline, up to 6 hrs
Relative Potency QTcB Interval
Selection of steepest part of dose response curve for Relative Potency: 2 and 6 inhalation dose pairs. Slope of A and B line compared with slope of D and E to obtain relative potency value. Twelve inhalation dose not utilized as not on steepest part of curve.
Time frame: Baseline up to 6 hrs
Max Heart Rate
max heart rate at the 2, 6, or 12 inhalations dose, assessed at multiple times over 6 hours
Time frame: Baseline through 6 hours
Plasma Potassium Level
maximum plasma levels of potassium at 2, 6 or 12 inhalations dose inhalations dose, assessed a multiple times over 6 hours.
Time frame: baseline through 6 hours
Max Plasma Glucose Level
maximum levels of glucose at the 2, 6 or 12 inhalations dose, assessed at multiple times over 6 hours.
Time frame: baseline through 6 hours
Max QTcB
For each dose, the 95% CIs for the mean difference for the test product versus the reference product were calculated.
Time frame: Baseline through 6 hours
Recruitment began 07 July 2014
| Milestone | Sequence 1 (A, F, B, E, C, D) | Sequence 2 (B, A, C, F, D, E) | Sequence 3 (C, B, D, A, E, F) | Sequence 4 (D, C, E, B, F, A) | Sequence 5 (E, D, F, C, A, B) | Sequence 6 (F, E, A, D, B, C ) |
|---|---|---|---|---|---|---|
| Started | 9 | 10 | 8 | 8 | 8 | 9 |
| Completed | 7 | 8 | 8 | 7 | 7 | 6 |
| Not completed | 2 | 2 | 0 | 1 | 1 | 3 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Poor inhalation technique | 0 | 1 | 0 | 0 | 0 | 2 |
| Withdrew: Protocol stop criteria | 0 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 |
Selection of steepest part of dose response curve for Relative Potency: 6 and 12 inhalation dose pairs. Slope of B and C line compared with slope of E and F to obtain relative potency value. Two inhalation dose not utilized as not on steepest part of curve.
| unitless | Test B and C vs Reference E and F |
|---|---|
| Relative Potency Max Heart Rate | 0.8619 (0.7209 to 1.00) |
Selection of steepest part of dose response curve for Relative Potency: 2 and 6 inhalation dose pairs. Slope of A and B line compared with slope of D and E to obtain relative potency value. Twelve inhalation dose not utilized as not on steepest part of curve.
| unitless | Test A and B vs Reference D and E |
|---|---|
| Relative Potency QTcB Interval | 1.0760 (0.8206 to 1.4238) |
max heart rate at the 2, 6, or 12 inhalations dose, assessed at multiple times over 6 hours
| bpm | Test Product A | Reference Product D | Test Product B | Reference Product E | Test Product C | Reference Product F |
|---|---|---|---|---|---|---|
| Max Heart Rate | 65.1 ± 10.9 | 65.5 ± 10.1 | 68.9 ± 11.0 | 69.9 ± 12.2 | 75.3 ± 13.3 | 76.8 ± 14.8 |
maximum plasma levels of potassium at 2, 6 or 12 inhalations dose inhalations dose, assessed a multiple times over 6 hours.
| mmol/L | Test Product A | Reference Product D | Test Product B | Reference Product E | Test Product C | Reference Product F |
|---|---|---|---|---|---|---|
| Plasma Potassium Level | 3.82 ± 0.19 | 3.78 ± 0.16 | 3.76 ± 0.20 | 3.75 ± 0.19 | 3.63 ± 0.24 | 3.61 ± 0.26 |
maximum levels of glucose at the 2, 6 or 12 inhalations dose, assessed at multiple times over 6 hours.
| mmol/L | Test Product A | Reference Product D | Test Product B | Reference Product E | Test Product C | Reference Product F |
|---|---|---|---|---|---|---|
| Max Plasma Glucose Level | 5.31 ± 0.49 | 5.31 ± 0.40 | 5.53 ± 0.65 | 5.62 ± 0.54 | 5.88 ± 0.66 | 5.98 ± 0.65 |
For each dose, the 95% CIs for the mean difference for the test product versus the reference product were calculated.
| ms | Test Product A | Reference Product D | Test Product B | Reference Product E | Test Product D | Reference Product F |
|---|---|---|---|---|---|---|
| Max QTcB | 422.3 ± 22.4 | 422.1 ± 23.7 | 430.0 ± 23.1 | 430.2 ± 21.4 | 441.0 ± 20.5 | 444.0 ± 26.7 |
Collected over Adverse events were collected for up to 2 months for each subject. The duration of the clinical phase of the study was 4 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Test Product A | 4/49 (8.2%) | 0/49 (0%) | 4/49 (8.2%) |
| Test Product B | 5/48 (10.4%) | 0/48 (0%) | 5/48 (10.4%) |
| Test Product C | 11/47 (23.4%) | 0/47 (0%) | 11/47 (23.4%) |
| Reference Product D | 5/47 (10.6%) | 0/47 (0%) | 5/47 (10.6%) |
| Reference Product E | 4/48 (8.3%) | 0/48 (0%) | 4/48 (8.3%) |
| Referencet Product F | 8/50 (16%) | 0/50 (0%) | 8/50 (16%) |
| Event | Test Product A | Test Product B | Test Product C | Reference Product D | Reference Product E | Referencet Product F |
|---|---|---|---|---|---|---|
| headacheNervous system disorders | 2/49 | 2/48 | 4/47 | 3/47 | 4/48 | 4/50 |
| DizzinessNervous system disorders | 0/49 | 0/48 | 4/47 | 0/47 | 0/48 | 0/50 |
| NervousnessPsychiatric disorders | 0/49 | 0/48 | 1/47 | 0/47 | 1/48 | 3/50 |
| Feeling HotGeneral disorders | 0/49 | 0/48 | 0/47 | 0/47 | 1/48 | 2/50 |
| PalpitationsCardiac disorders | 0/49 | 0/48 | 1/47 | 0/47 | 0/48 | 2/50 |
| tremorNervous system disorders | 0/49 | 0/48 | 0/47 | 0/47 | 0/48 | 2/50 |
| FlushingVascular disorders | 0/49 | 0/48 | 0/47 | 0/47 | 0/48 | 2/50 |
| VomitingGastrointestinal disorders | 0/49 | 0/48 | 0/47 | 1/47 | 0/48 | 0/50 |
| Feeling ColdGeneral disorders | 0/49 | 0/48 | 1/47 | 0/47 | 0/48 | 0/50 |
| ECG QT prolongedInvestigations | 0/49 | 0/48 | 1/47 | 0/47 | 0/48 | 1/50 |
all subjects who received at least one test and one reference product for same dose
| Age, Continuous(years) | All Subjects |
|---|---|
| Mean | 33.5 ± 10.8 |
| Sex: Female, Male(Participants) | All Subjects |
|---|---|
| Female | 23 |
| Male | 29 |
| Race (NIH/OMB)(Participants) | All Subjects |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 46 |
| More than one race | 0 |
| Unknown or Not Reported | 4 |
| Region of Enrollment(participants) | All Subjects |
|---|---|
| United Kingdom | 52 |
| BMI(kg/m2) | All Subjects |
|---|---|
| Mean | 23.6 ± 1.8 |
| forced expiratory volume at one second(% predicted normal) | All Subjects |
|---|---|
| Mean | 101.19 ± 10.74 |
Plan to share: No
The record gives a start of Jul 2014, a primary completion of Oct 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2020, 6 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Salmeterol Xinafoate · Fluticasone
Kindeva Drug Delivery